Results 31 to 40 of about 3,887,212 (164)

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

Frontiers in Endocrinology, 2021
IntroductionPrimary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible.
Alexis Huot Daneault, Mélanie Desaulniers, Jean-Mathieu Beauregard, Alexis Beaulieu, Frédéric Arsenault, Geneviève April, Éric Turcotte, François-Alexandre Buteau   +7 more
doaj   +1 more source

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms [PDF]

, 2018
Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study.In our center, 2294 patients were screened ...
Baum, Richard P., Hommann, Merten, Robiller, Franz C., Dieter Hörsch, Aviral Singh, Dirk Mueller, Lambin, Philippe, Richard P. Baum, Mueller, Dirk, Daniel Kaemmerer, Arthur Jochems, Jochems, Arthur, Holger Franz, Kaemmerer, Daniel, Karin Niepsch, Franz C. Robiller, Kulkarni, Harshad R., Philippe Lambin, Vikas Prasad, Prasad, Vikas, Holger, Franz, Merten Hommann, Harshad R. Kulkarni, Singh, Aviral, Horsch, Dieter, Niepsch, Karin   +25 more
core   +2 more sources

Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group: Neuroendocrine Tumors

Brazilian Journal of Oncology, 2018
Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms with variable prognoses and clinical presentations. Therefore their therapeutic management is challenging, involving a real multidisciplinary approach composed of medical ...
Duilio R. Rocha, Juliana F. Rego, Rachel P. Riechelmann   +2 more
doaj   +1 more source

ENETS concensus guidelines for the standards of care in Neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs [PDF]

, 2009
The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT.
Komminoth, P, European-Neuroendocrine-Tumor, Society, Kos-Kudla, B, de Herder, WW, Mallorca-Consensus-Conference, Participants, Lebtahi, R, Krenning, Eric, Kwekkeboom, DJ, de Herder, W.W., Krenning, EP, Plöckinger, U, Kwekkeboom, Dik   +11 more
core   +1 more source

Peptide Receptor Radionuclide Therapy & Oncology [PDF]

, 2017
Neuroendocrine tumors (NETs) are rare neoplasms with differences in clinical presentation, course and prognosis. Most of the NETs express the somatostatine receptor, which can be utilized for imaging and therapy.
Bergsma, H. (Hendrik)
core   +1 more source

Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience

Xiehe Yixue Zazhi, 2022
Peptide receptor radionuclide therapy (PRRT) is one of the advanced therapies for neuroendocrine neoplasms (NENs), which can relieve the symptoms and improve the quality of life of patients with NENs with good tolerance to the treatment.However, since ...
LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei   +5 more
doaj   +1 more source

Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma,
Jenny S W Yun, Chris McCormack, Michelle Goh, Cherie Chiang   +3 more
doaj   +1 more source

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Journal of Cancer Research and Practice
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT).
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine   +10 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Frontiers in Endocrinology, 2022
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited.
Sriram Gubbi, Christian A. Koch, Christian A. Koch, Joanna Klubo-Gwiezdzinska   +3 more
doaj   +1 more source

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source